Literature DB >> 17021820

Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.

Ram Varma1, Suzanne Hector, William R Greco, Kimberly Clark, Lesleyann Hawthorn, Carl Porter, Lakshmi Pendyala.   

Abstract

PURPOSE: As a follow-up to our previous findings that platinum drugs induce a key enzyme in polyamine catabolism, gene expression profiling and mathematical modeling were used to define the effects of cisplatin and oxaliplatin on the expression of polyamine metabolic pathway genes in A2780 human ovarian carcinoma cells.
METHODS: Time-course and concentration-effect experiments were each carried out with cisplatin or oxaliplatin in two separate experiments and cells subjected to gene expression profiling using Affymetrix array technology. Time-course data were modeled using exponential increase and decrease models. Concentration-effect data were modeled using a four parameter Hill model.
RESULTS: Gene expression profiling of human ovarian carcinoma A2780 cells after exposure to either cisplatin or oxaliplatin indicates that the expression of several genes involved in polyamine pathway is affected by the platinum drugs. Mathematical/Statistical modeling of the data from time-course and concentration-effect experiments of gene expression from nine polyamine pathway genes represented on the HGU95Av2 chip, indicates that three biosynthetic pathway genes (SAMDC, ODC1 and SRM) are down-regulated and one catabolic pathway gene (SSAT) is up-regulated. Expression changes were similar for different probesets for a given gene on the array. Studies on the induction of SSAT by platinum drugs suggested by the Affymetrix data have been previously validated from this laboratory (Hector et al. in Mol Cancer Ther 3:813-822, 2004). Here, the effects of oxaliplatin exposure on SAMDC and ODC observed by Affymetix are validated with real time QRT-PCR.
CONCLUSION: The data indicate a concerted effect of platinum drugs on the polyamine metabolic pathway with down-regulation in the expression of several enzyme genes involved in biosynthesis and many-fold up-regulation in expression of SSAT, an acetylating enzyme gene that is critically involved in polyamine catabolism and export.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021820     DOI: 10.1007/s00280-006-0325-3

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.

Authors:  Ramakumar Tummala; Paula Diegelman; Suzanne Hector; Debora L Kramer; Kimberly Clark; Patricia Zagst; Gerald Fetterly; Carl W Porter; Lakshmi Pendyala
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-05       Impact factor: 3.333

2.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers.

Authors:  Xiaofei Chang; Constance L Monitto; Semra Demokan; Myoung Sook Kim; Steven S Chang; Xiaoli Zhong; Joseph A Califano; David Sidransky
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

3.  Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells.

Authors:  Ramakumar Tummala; Paula Diegelman; Sonia M Fiuza; Luis A E Batista de Carvalho; Maria Paula M Marques; Debora L Kramer; Kimberly Clark; Slavoljub Vujcic; Carl W Porter; Lakshmi Pendyala
Journal:  Oncol Rep       Date:  2010-07       Impact factor: 3.906

Review 4.  Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma.

Authors:  Nicholas F Evageliou; Michael D Hogarty
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

5.  ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.

Authors:  Michael D Hogarty; Murray D Norris; Kimberly Davis; Xueyuan Liu; Nicholas F Evageliou; Candace S Hayes; Bruce Pawel; Rong Guo; Huaqing Zhao; Eric Sekyere; Joanna Keating; Wayne Thomas; Ngan Ching Cheng; Jayne Murray; Janice Smith; Rosemary Sutton; Nicola Venn; Wendy B London; Allen Buxton; Susan K Gilmour; Glenn M Marshall; Michelle Haber
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 6.  Polyamine catabolism and disease.

Authors:  Robert A Casero; Anthony E Pegg
Journal:  Biochem J       Date:  2009-07-15       Impact factor: 3.857

7.  The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Authors:  Allison Pledgie-Tracy; Madhavi Billam; Amy Hacker; Michele D Sobolewski; Patrick M Woster; Zhe Zhang; Robert A Casero; Nancy E Davidson
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-30       Impact factor: 3.333

8.  Silencing of the polyamine catabolic key enzyme SSAT prevents CDK inhibitor-induced apoptosis in Caco-2 colon cancer cells.

Authors:  A Çoker; E D Arısan; N Palavan-Ünsal
Journal:  Mol Med Rep       Date:  2012-01-30       Impact factor: 2.952

9.  Transcriptional profiling of the dose response: a more powerful approach for characterizing drug activities.

Authors:  Rui-Ru Ji; Heshani de Silva; Yisheng Jin; Robert E Bruccoleri; Jian Cao; Aiqing He; Wenjun Huang; Paul S Kayne; Isaac M Neuhaus; Karl-Heinz Ott; Becky Penhallow; Mark I Cockett; Michael G Neubauer; Nathan O Siemers; Petra Ross-Macdonald
Journal:  PLoS Comput Biol       Date:  2009-09-18       Impact factor: 4.475

10.  A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.

Authors:  Tracy Murray Stewart; Daniel Von Hoff; Michael Fitzgerald; Laurence J Marton; Carlos H Roberto Becerra; Thomas E Boyd; Paul R Conkling; Lawrence E Garbo; Robert M Jotte; Donald A Richards; David A Smith; Joe J Stephenson; Nicholas J Vogelzang; Hillary H Wu; Robert A Casero
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-19       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.